sellModerate cluster of 310b5-1 plan
GARCIA ERNEST C. II sold $38M of CVNA
owner at CARVANA CO.. 200,000 shares at an average of $192.38, traded Oct 15, 2024, filed Oct 17, 2024.
Warning score
52Value
$38M
200,000 shares
Holdings after
0
-200% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-24-115411, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 15, 2024 | CConversion Class A Common Stock10b5-1 | +100,000 | - | - | 100,000 | Oct 17, 2024 |
| Oct 15, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -5,400 | $189.41 | $1.0M | 94,600 | Oct 17, 2024 |
| Oct 15, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -13,590 | $190.93 | $2.6M | 81,010 | Oct 17, 2024 |
| Oct 15, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -56,815 | $191.61 | $11M | 24,195 | Oct 17, 2024 |
| Oct 15, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -16,647 | $192.57 | $3.2M | 7,548 | Oct 17, 2024 |
| Oct 15, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -7,448 | $193.48 | $1.4M | 100 | Oct 17, 2024 |
| Oct 15, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -100 | $194.46 | $19k | 0 | Oct 17, 2024 |
| Oct 16, 2024 | CConversion Class A Common Stock10b5-1 | +100,000 | - | - | 100,000 | Oct 17, 2024 |
| Oct 16, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -6,111 | $190.05 | $1.2M | 93,889 | Oct 17, 2024 |
| Oct 16, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -8,179 | $190.97 | $1.6M | 85,710 | Oct 17, 2024 |
| Oct 16, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -8,519 | $192.07 | $1.6M | 77,191 | Oct 17, 2024 |
| Oct 16, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -33,655 | $193.19 | $6.5M | 43,536 | Oct 17, 2024 |
| Oct 16, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -41,746 | $193.94 | $8.1M | 1,790 | Oct 17, 2024 |
| Oct 16, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -1,790 | $194.82 | $349k | 0 | Oct 17, 2024 |
| Oct 15, 2024 | JOther Class B Common Stock10b5-1 | -100,000 | - | - | 38,158,131 | Oct 17, 2024 |
| Oct 16, 2024 | JOther Class B Common Stock10b5-1 | -100,000 | - | - | 38,058,131 | Oct 17, 2024 |
| Oct 15, 2024 | CConversion Class A Unitsderivative10b5-1 | -125,000 | $0.00 | $0 | 47,697,663 | Oct 17, 2024 |
| Oct 16, 2024 | CConversion Class A Unitsderivative10b5-1 | -125,000 | $0.00 | $0 | 47,572,663 | Oct 17, 2024 |
Related signals
Other insiders at CARVANA CO. and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 60Notable | sell 4 | CVNA CARVANA CO. | KEETON RYAN S. Chief Brand Officer | $6.2M | 24,845 | |
| 55Moderate | sell 410b5-1 | CVNA CARVANA CO. | PLATT IRA J. director | $6.1M | 25,000 | |
| 40Moderate | sell 410b5-1 | CVNA CARVANA CO. | GILL DANIEL J. Chief Product Officer | $11M | 44,000 | |
| 27Weak | sell 410b5-1 | CVNA CARVANA CO. | JENKINS MARK W. Chief Financial Officer | $2.6M | 10,000 | |
| 35Weak | sell 510b5-1 | CVNA CARVANA CO. | GILL DANIEL J. Chief Product Officer | $2.8M | 11,000 | |
| 47Moderate | sell 610b5-1 | CVNA CARVANA CO. | JENKINS MARK W. Chief Financial Officer | $9.9M | 40,000 | |
| 55Moderate | sell 6 | CVNA CARVANA CO. | SULLIVAN GREGORY B director | $1.2M | 5,000 | |
| 47Moderate | sell 610b5-1 | CVNA CARVANA CO. | JENKINS MARK W. Chief Financial Officer | $61M | 268,495 | |
| 25Weak | sell 610b5-1 | CVNA CARVANA CO. | BREAUX PAUL W. See Remarks | $7.2M | 30,000 | |
| 36Weak | sell 610b5-1 | CVNA CARVANA CO. | HUSTON BENJAMIN E. Chief Operating Officer | $730k | 3,043 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.